[{"orgOrder":0,"company":"Talphera","sponsor":"XOMA","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Sufentanil Citrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Talphera","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Talphera \/ XOMA","highestDevelopmentStatusID":"12","companyTruncated":"Talphera \/ XOMA"},{"orgOrder":0,"company":"Talphera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Nafamostat","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Talphera","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Talphera \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Talphera \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Talphera

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Talphera's lead product candidate, Niyad is a lyophilized formulation of nafamostat mesylate and is currently being studied under an IDE as an anticoagulant for the extracorporeal circuit.

                          Brand Name : Niyad

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 19, 2024

                          Lead Product(s) : Nafamostat

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : XOMA acquired an economic interest in DSUVIA® (sufentanil sublingual tablet), an opioid agonist, indicated for use in adults, for the management of acute pain, from Talphera.

                          Brand Name : Dsuvia

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          January 18, 2024

                          Lead Product(s) : Sufentanil Citrate

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : XOMA

                          Deal Size : $8.0 million

                          Deal Type : Acquisition

                          blank